PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

NCT00511043 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Manufacturer stopped drug development

Conditions

Lymphoma, Large-Cell, Diffuse

Interventions

DRUG: PTK787

Sponsor

David Rizzieri, MD

Collaborators

[object Object]